Full Press Release Details
The Center for Cell and Gene Therapy
at Baylor College of Medicine to
Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019
- January 15, 2019 - Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology
company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies
and solid tumor indications, today reported that data from four abstracts-including three oral presentations-were
accepted for presentation at the Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Blood and Marrow
Transplantation and the Center for International Blood and Marrow Transplant Research
(ASBMT and CIBMTR). The studies summarize data achieved using multi-tumor antigen specific T cells that were developed
at Baylor College of Medicine in the laboratories of Dr. Swati Naik, Dr. Ann Leen, and Dr. Premal Lulla, and exclusively licensed
of ASBMT and CIBMTR 2019 will take place in Houston, TX from February 20-24.
Oral Presentation Details
Title: "Targeting Lymphomas Using Non-Engineered, Multi-Antigen-Specific T Cells" (Abstract #24)
Title: Session C - Lymphoma and Myeloma
Wednesday, February 20, 2019, 5:00 p.m. CST
Title: "Administering Leukemia-Directed Donor Lymphocytes to Patients with AML or MDS to Prevent or Treat Post-Allogeneic
HSCT Relapse" (Abstract #11)
Session A - Acute and Chronic Leukemia
Wednesday, February 20, 2019, 5:45 p.m. CST
Presentation Title: "Adoptive
T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor-Associated Antigens" (Abstract #78)
Session Title: Session
K - Immune and Gene Therapy
Session Date/Time: Saturday, February
23, 2019, 5:00 p.m. CST
Poster Presentation Details
Title: "Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma" (Abstract #621)
Date/Time: Saturday, February 23, 6:45 p.m. CST
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies
for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on
the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets)
and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets
and acts to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically
engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less
expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit.
As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current
gene-modified CAR-T and TCR-based therapies.
Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of metastatic solid
tumors, including the Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and the HER2/neu program (TPIV100/110)
for breast cancer, currently in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology
named PolyStart that can enhance the ability of the immune system to recognize and destroy diseased cells.
For additional information, please call toll free at (904) 862-6490 or visit: markertherapeutics.com
To receive future press releases via email, please visit: https://markertherapeutics.com/email-alerts/
Forward-Looking Statement Disclaimer
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance
or other matters, are "forward-looking statements". Forward-looking statements include statements regarding our intentions,
beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities
relating to our multi-tumor antigen specific T cell therapies; our TPIV200 and TPIV100/110 programs and our PolyStart program;
the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment
of diseases; and, the timing and success of our clinical trials, as well as multi-tumor antigen specific T cell clinical trials
conducted by Baylor College of Medicine. Forward-looking statements are by their nature subject to risks, uncertainties and other
factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and
factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings
which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update our forward-looking statements whether
as a result of new information, future events or otherwise, after the date of this press release.
Marker Therapeutics, Inc.